General Administration of Sport of China

Optinose Reports Third Quarter 2023 Financial Results and Operational Updates

Retrieved on: 
Thursday, November 9, 2023

YARDLEY, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) --  Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended September 30, 2023, and provided operational updates.

Key Points: 
  • We are pleased with the progress we made in the third quarter towards our 2023 operating objectives while sharply reducing expenses.
  • Today’s results show that we are outperforming our initial expectations for 2023 XHANCE net revenues while operating far more efficiently and preparing our organization for a successful launch in 2024.
  • Previously, the Company expected XHANCE net revenues for the full year of 2023 to be between $64.0 to $70.0 million.
  • Members of the Company’s leadership team will host a conference call and presentation to discuss financial results and corporate updates beginning at 8:00 a.m. Eastern Time today.

Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, November 8, 2023

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results and provided a corporate update for the third quarter ended September 30, 2023.

Key Points: 
  • In October 2023, Tenaya shared positive Phase 1 data for TN-301 at the 2023 Heart Failure Society of America (HFSA) Annual Scientific Meeting.
  • General & Administrative (G&A) Expenses: G&A expenses for the quarter ended September 30, 2023, were $7.8 million.
  • Non-cash stock-based compensation included in G&A expense was $2.2 million for the quarter ended September 30, 2023.
  • Net Loss: Net loss for the quarter ended September 30, 2023, was $29.1 million, or $0.39 per share.

NMG Provides Quarterly Update: Changing Market Dynamics and Intensified Commercial Negotiations Underpin Phase-2 Growth

Retrieved on: 
Thursday, November 9, 2023

NMG operates a concentrator, two shaping modules, two commercial-scale purification furnaces, and a coating unit for a nameplate capacity of 2,000 tonnes per annum (“tpa”).

Key Points: 
  • NMG operates a concentrator, two shaping modules, two commercial-scale purification furnaces, and a coating unit for a nameplate capacity of 2,000 tonnes per annum (“tpa”).
  • NMG has successfully and repeatedly produced on-specifications batches of active anode material as per potential customers’ individual requirements.
  • NMG has also appointed Pomerleau as Construction Manager for the pre-construction stage of its Phase-2 commercial facilities.
  • NMG is focused on securing the best agreements and positioning the Company for long-term growth in the Western industry.

Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Wednesday, November 8, 2023

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the third quarter ending September 30, 2023 and highlighted recent progress.

Key Points: 
  • Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the third quarter ending September 30, 2023 and highlighted recent progress.
  • Verastem Oncology ended the third quarter of 2023 with cash, cash equivalents and investments of $165.7 million.
  • Research & development expenses for the 2023 Quarter were $13.9 million, compared to $11.3 million for the 2022 Quarter.
  • Selling, general & administrative expenses for the 2023 Quarter were $7.4 million, compared to $6.4 million for the 2022 Quarter.

Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, November 9, 2023

Rallybio Corporation (Nasdaq: RLYB) today reported financial results for the third quarter ended September 30, 2023 and provided an update on recent program and corporate developments.

Key Points: 
  • Rallybio Corporation (Nasdaq: RLYB) today reported financial results for the third quarter ended September 30, 2023 and provided an update on recent program and corporate developments.
  • Poster presentation of abstract for the ongoing natural history study at the 65th American Society of Hematology Annual Meeting in December 2023.
  • Third Quarter 2023 Financial Results:
    Research & Development (R&D) Expenses: R&D expenses were $13.3 million for the third quarter of 2023, compared to $12.1 million for the same period in 2022.
  • Cash Position: As of September 30, 2023, cash, cash equivalents and marketable securities were $121.4 million.

Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 8, 2023

CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported third quarter 2023 financial results and provided an update on the business and its clinical and pipeline progress.

Key Points: 
  • Beam anticipates that currently consented patients are sufficient to both fill the sentinel cohort (n=3) and to initiate the expansion cohort.
  • Research & Development (R&D) Expenses: R&D expenses were $100.0 million for the third quarter of 2023, compared to $85.3 million for the third quarter of 2022.
  • General & Administrative (G&A) Expenses: G&A expenses were $25.4 million for the third quarter of 2023, compared to $21.8 million for the third quarter of 2022.
  • Net Loss: Net loss was $96.1 million for the third quarter of 2023, or $1.22 per share, compared to $109.6 million for the third quarter of 2022, or $1.56 per share.

Tritium Implements Strategic Plan to Achieve 2024 Profitability

Retrieved on: 
Wednesday, November 8, 2023

BRISBANE, Australia, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Tritium DCFC Limited (Tritium) (Nasdaq: DCFC), a global leader in direct current (DC) fast chargers for electric vehicles (EVs), today announced the implementation of business measures designed to achieve a path to profitability in 2024 and reduce external capital requirements.

Key Points: 
  • BRISBANE, Australia, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Tritium DCFC Limited (Tritium) (Nasdaq: DCFC), a global leader in direct current (DC) fast chargers for electric vehicles (EVs), today announced the implementation of business measures designed to achieve a path to profitability in 2024 and reduce external capital requirements.
  • The plan sees Tritium improve operational efficiency and margins to drive profitability and shareholder value by consolidating its global manufacturing operations into its scaled plant in Lebanon, Tennessee, and reduce selling general & administrative (SG&A) expenses via plans to decrease specific headcount and professional fees.
  • “While we continue to build on our recently reported financial results, which include achieving record revenue and gross margin, strategic restructuring of our business is necessary to drive both profitability and shareholder value,” said Tritium CEO Jane Hunter.
  • “This transition is aligned with the company’s plan to be profitable in 2024.

Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update

Retrieved on: 
Tuesday, November 7, 2023

CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended September 30, 2023, and provided a business update.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended September 30, 2023, and provided a business update.
  • Research & Development (R&D) Expenses: R&D expenses for the third quarter of 2023 were $27.6 million, compared to $16.9 million for the third quarter of 2022.
  • General & Administrative (G&A) Expenses: G&A expenses for the third quarter of 2023 were $7.7 million, compared to $7.2 million for the third quarter of 2022.
  • Net Loss: Net loss for the third quarter of 2023 was $33.2 million, compared to $23.8 million for the third quarter of 2022.

Noodles & Company Announces Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023

BROOMFIELD, Colo., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Noodles & Company (Nasdaq: NDLS) today announced financial results for its third quarter ended October 3, 2023.

Key Points: 
  • BROOMFIELD, Colo., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Noodles & Company (Nasdaq: NDLS) today announced financial results for its third quarter ended October 3, 2023.
  • Restaurant contribution margin increased to 16.4% in the third quarter of 2023, compared to 14.4% in the third quarter of 2022.
  • Based upon management’s current assessment following third quarter results, the Company has revised guidance related to its 2023 performance.
  • Noodles & Company will host a conference call to discuss its third quarter financial results on Tuesday, November 7, 2023 at 4:30 PM Eastern Time.

Entrada Therapeutics Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today reported financial results for the third quarter ending September 30, 2023, and highlighted recent business updates.

Key Points: 
  • In July 2023, Entrada entered into a license agreement to advance the development of ENTR-501 with Pierrepont Therapeutics, Inc., a mitochondrial disease-focused company.
  • Research & Development (R&D) Expenses: R&D expenses were $22.2 million for the third quarter of 2023, compared to $19.0 million for the same period in 2022.
  • General & Administrative (G&A) Expenses: G&A expenses were $7.5 million for the third quarter of 2023, compared to $7.0 million for the same period in 2022.
  • Net Income (Loss): Net income was $35.5 million for the third quarter of 2023, compared to a net loss of $(25.1) million for the same period in 2022.